Regencell Bioscience Holdings Limited (RGC)
USD 29.0
(-0.41%)
USD 29.0
(-0.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -4.3 Million USD | 26.73% |
| 2023 | -5.87 Million USD | 20.9% |
| 2022 | -7.42 Million USD | -451.16% |
| 2021 | -1.34 Million USD | -65.78% |
| 2020 | -812.37 Thousand USD | -107.77% |
| 2019 | -390.99 Thousand USD | -100.35% |
| 2018 | 112.3 Million USD | -34.1% |
| 2017 | 170.4 Million USD | 11.08% |
| 2016 | 153.4 Million USD | 45.27% |
| 2015 | 105.6 Million USD | 0.0% |
| 2013 | 157.7 Million USD | 8.91% |
| 2012 | 144.8 Million USD | 86.6% |
| 2011 | 77.6 Million USD | -18.74% |
| 2010 | 95.5 Million USD | 32.64% |
| 2009 | 72 Million USD | 0.0% |
| 2007 | 363 Million USD | 322.09% |
| 2006 | 86 Million USD | 4.88% |
| 2005 | 82 Million USD | -55.68% |
| 2004 | 185 Million USD | 0.0% |
| 2002 | 117 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -2.23 Million USD | 0.0% |
| 2024 Q2 | -1033.31 USD | 0.0% |
| 2024 Q1 | -1033.31 USD | 99.96% |
| 2023 FY | -5.87 Million USD | 20.9% |
| 2023 Q1 | -1613.69 USD | 99.96% |
| 2023 Q2 | -3.22 Million USD | -199900.0% |
| 2023 Q4 | -2.64 Million USD | -199900.0% |
| 2023 Q3 | -1321.88 USD | 99.96% |
| 2022 Q3 | -1927.25 USD | 99.95% |
| 2022 Q4 | -3.93 Million USD | -204115.65% |
| 2022 FY | -7.42 Million USD | -451.16% |
| 2022 Q1 | -1795.73 USD | -254.57% |
| 2022 Q2 | -3.65 Million USD | -203651.41% |
| 2021 FY | -1.34 Million USD | -65.78% |
| 2021 Q3 | -506.45 USD | -203.4% |
| 2021 Q4 | -506.45 USD | 0.0% |
| 2021 Q2 | -166.92 USD | 0.0% |
| 2021 Q1 | -166.92 USD | 35.09% |
| 2020 Q2 | -149.01 USD | 0.0% |
| 2020 FY | -812.37 Thousand USD | -107.77% |
| 2020 Q4 | -257.18 USD | 0.0% |
| 2020 Q3 | -257.18 USD | -72.59% |
| 2020 Q1 | -149.01 USD | 0.0% |
| 2019 FY | -390.99 Thousand USD | -100.35% |
| 2018 FY | 112.3 Million USD | -34.1% |
| 2018 Q2 | 28.9 Million USD | 153.51% |
| 2018 Q1 | 11.4 Million USD | -51.69% |
| 2017 Q4 | 23.6 Million USD | -51.24% |
| 2017 Q3 | 48.4 Million USD | -10.2% |
| 2017 Q2 | 53.9 Million USD | 27.42% |
| 2017 Q1 | 42.3 Million USD | 26.27% |
| 2017 FY | 170.4 Million USD | 11.08% |
| 2016 Q4 | 33.5 Million USD | -17.69% |
| 2016 FY | 153.4 Million USD | 45.27% |
| 2016 Q3 | 40.7 Million USD | -26.0% |
| 2016 Q2 | 55 Million USD | 151.14% |
| 2016 Q1 | 21.9 Million USD | -58.99% |
| 2015 FY | 105.6 Million USD | 0.0% |
| 2015 Q4 | 53.4 Million USD | 131.17% |
| 2015 Q2 | 46.3 Million USD | 73.41% |
| 2015 Q3 | 23.1 Million USD | -50.11% |
| 2015 Q1 | 26.7 Million USD | -21.01% |
| 2014 Q4 | 33.8 Million USD | 2916.67% |
| 2014 Q2 | 24 Million USD | -68.04% |
| 2014 Q1 | 75.1 Million USD | 108.03% |
| 2014 Q3 | -1.2 Million USD | -105.0% |
| 2013 Q4 | 36.1 Million USD | 60.44% |
| 2013 FY | 157.7 Million USD | 8.91% |
| 2013 Q2 | 37.3 Million USD | 55.42% |
| 2013 Q1 | 24 Million USD | -35.48% |
| 2013 Q3 | 22.5 Million USD | -39.68% |
| 2012 Q4 | 37.2 Million USD | -19.65% |
| 2012 FY | 144.8 Million USD | 86.6% |
| 2012 Q1 | 25 Million USD | -28.16% |
| 2012 Q2 | 4.1 Million USD | -83.6% |
| 2012 Q3 | 46.3 Million USD | 1029.27% |
| 2011 Q3 | -23.6 Million USD | -272.26% |
| 2011 FY | 77.6 Million USD | -18.74% |
| 2011 Q1 | 42.6 Million USD | 238.05% |
| 2011 Q2 | 13.7 Million USD | -67.84% |
| 2011 Q4 | 34.8 Million USD | 247.46% |
| 2010 Q1 | -2 Million USD | -105.0% |
| 2010 FY | 95.5 Million USD | 32.64% |
| 2010 Q4 | 12.6 Million USD | -21.24% |
| 2010 Q3 | 16 Million USD | -54.93% |
| 2010 Q2 | 35.5 Million USD | 1875.0% |
| 2009 Q2 | 30 Million USD | -6.25% |
| 2009 Q3 | 21 Million USD | -30.0% |
| 2009 Q1 | 32 Million USD | 146.15% |
| 2009 FY | 72 Million USD | 0.0% |
| 2009 Q4 | 40 Million USD | 90.48% |
| 2008 Q1 | 58 Million USD | 11.54% |
| 2008 Q4 | 13 Million USD | 533.33% |
| 2008 Q3 | -3 Million USD | -112.5% |
| 2008 Q2 | 24 Million USD | -58.62% |
| 2007 FY | 363 Million USD | 322.09% |
| 2007 Q1 | 30 Million USD | 87.5% |
| 2007 Q2 | 29 Million USD | -3.33% |
| 2007 Q3 | 229 Million USD | 689.66% |
| 2007 Q4 | 52 Million USD | -77.29% |
| 2006 Q2 | 35 Million USD | 105.88% |
| 2006 Q3 | 11 Million USD | -68.57% |
| 2006 FY | 86 Million USD | 4.88% |
| 2006 Q4 | 16 Million USD | 45.45% |
| 2006 Q1 | 17 Million USD | -35.61% |
| 2005 Q4 | 26.4 Million USD | 101.53% |
| 2005 FY | 82 Million USD | -55.68% |
| 2005 Q1 | 27.8 Million USD | 285.33% |
| 2005 Q2 | 55 Million USD | 97.84% |
| 2005 Q3 | 13.1 Million USD | -76.18% |
| 2004 Q3 | 22 Million USD | -84.4% |
| 2004 Q1 | 44 Million USD | 266.67% |
| 2004 Q2 | 141 Million USD | 220.45% |
| 2004 Q4 | -15 Million USD | -168.18% |
| 2004 FY | 185 Million USD | 0.0% |
| 2003 Q4 | 12 Million USD | -65.71% |
| 2003 Q2 | 81 Million USD | 125.0% |
| 2003 Q3 | 35 Million USD | -56.79% |
| 2003 Q1 | 36 Million USD | -5.26% |
| 2002 FY | 117 Million USD | 0.0% |
| 2002 Q4 | 38 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Journey Medical Corporation | -3.85 Million USD | -11.649% |
| Safety Shot Inc | -15.08 Million USD | 71.479% |
| Bright Green Corporation | -13.12 Million USD | 67.231% |
| Alvotech | -551.73 Million USD | 99.22% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 45.339% |
| Cosmos Health Inc. | -18.54 Million USD | 76.8% |
| Dynavax Technologies Corporation | -6.38 Million USD | 32.668% |
| Embecta Corp. | 70.4 Million USD | 106.111% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 97.944% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 96.92% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 110.253% |
| PainReform Ltd. | -9.34 Million USD | 53.962% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 4.532% |
| SCYNEXIS, Inc. | 67.04 Million USD | 106.417% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -38.835% |
| Alpha Teknova, Inc. | -36.78 Million USD | 88.304% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 122.908% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 108.933% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 4.532% |
| Procaps Group, S.A. | 42.54 Million USD | 110.112% |
| Theratechnologies Inc. | -23.95 Million USD | 82.044% |
| Harrow Health, Inc. | -24.41 Million USD | 82.377% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 11.027% |
| Biofrontera Inc. | -20.13 Million USD | 78.631% |
| DURECT Corporation | -27.62 Million USD | 84.427% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 426.887% |
| Cronos Group Inc. | -73.96 Million USD | 94.184% |
| OptiNose, Inc. | -35.48 Million USD | 87.876% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.571% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 89.806% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 117.987% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 186.994% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 2822.113% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 31.492% |
| Radius Health, Inc. | -25.79 Million USD | 83.32% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 30.2% |
| ProPhase Labs, Inc. | -16.78 Million USD | 74.366% |
| Phibro Animal Health Corporation | 2.41 Million USD | 278.056% |
| Procaps Group S.A. | 42.54 Million USD | 110.112% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 58.145% |
| Viatris Inc. | 54.7 Million USD | 107.864% |
| Rockwell Medical, Inc. | -8.43 Million USD | 49.024% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 72.849% |
| SIGA Technologies, Inc. | 68.06 Million USD | 106.32% |
| Tilray Brands, Inc. | -244.98 Million USD | 98.244% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 135.81% |
| Shineco, Inc. | -22.44 Million USD | 80.837% |
| PetIQ, Inc. | 2.13 Million USD | 301.869% |
| Incannex Healthcare Limited | -18.45 Million USD | 76.695% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 101.723% |
| Alimera Sciences, Inc. | -20.13 Million USD | 78.632% |
| Silver Spike Investment Corp. | 7.34 Million USD | 158.607% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.704% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 34.749% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 47.302% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 75.966% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 78.552% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 97.316% |
| Hempacco Co., Inc. | -13.12 Million USD | 67.227% |
| Talphera, Inc. | -18.39 Million USD | 76.617% |
| Alvotech | -551.73 Million USD | 99.22% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 112.07% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.317% |
| Currenc Group, Inc. | -15.3 Million USD | 71.895% |
| Kamada Ltd. | 8.28 Million USD | 151.929% |
| Indivior PLC | 2 Million USD | 315.092% |
| Evoke Pharma, Inc. | -7.79 Million USD | 44.794% |
| Flora Growth Corp. | -57.03 Million USD | 92.458% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 78.552% |
| Evolus, Inc. | -61.68 Million USD | 93.026% |
| HUTCHMED (China) Limited | 100.78 Million USD | 104.269% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 103.128% |
| Akanda Corp. | -32.27 Million USD | 86.671% |